Pharma in the Post-COVID Era
Prescient’s industry snapshot points the direction of change for pharma businesses
COVID-19 has propelled the pharma industry onto the front pages with the desperate search for a vaccine. Below the headlines, another story has emerged as non-COVID-19 patients require continuity of treatment for conditions such as cancer and heart disease even as healthcare providers come under increasing pressure.
All industries are struggling to maintain their day-to-day operations under the new conditions imposed by the pandemic – and pharma is not immune.
Prescient is a vital partner to the pharma industry marshalling its way through this new landscape; from management and supply channels to clinical trial activity, pharma’s decision makers need the latest information and analysis to reimagine their strategy with the best possible intelligence.
“Pharma in the Post-COVID Era – Adapting to the New Normal” is the latest white paper from Prescient, providing a comprehensive view of the state of the pharma industry today, its response to COVID-19 and how the future looks for the industry as a whole.
In this whitepaper, Prescient’s research and analysis reveals:
- Macroeconomic factors that have been exacerbated by COVID-19 and how these will impact the profitability of pharma businesses
- How the major pharma players are affected by COVID-19 across four areas of operations (business activity, manufacturing and supply, sales and marketing, and clinical trials)
- How the processes of discovery and trial design must adapt for the post-COVID era
Pharma, like all industries, is facing a challenge that will force businesses to re-examine almost every assumption. Download this exclusive Prescient whitepaper to learn how to survive and thrive in the post-COVID era.